Intra-Cellular Therapies (ITI) is developing novel drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the Central Nervous System (CNS). Combining the efforts of medicinal chemists, pharmacologists, biologists and clinical development scientists the company has developed ITI-007 is a novel first-in-class 5-HT2A antagonist, Dopamine receptor phosphoprotein modulator (DPPM) designed to treat multiple deficits in patients with schizophrenia while lacking the side-effects of existing antipsychotic drugs. The firm has also developed a technology platform, called CNSProfile that is capable of generating a unique molecular signature for drug compounds. This profile provides a proprietary window into the intracellular action of CNS drugs or drug candidates. This tool is used to fingerprint the intracellular molecular actions of existing drugs and to drive internal drug discovery and development. Technology has also enabled the company to examine the toxic effects of brain damaging nerve agents enablingcollaborative efforts to develop antidotes to chemical warfare agents. Through a reverse merger with public shell firm Oneida Resources, the firms became a public reporting entity: Intra-Cellular Therapies (ITI).
